Despite a string of US policy initiatives designed to curb medicine pricing under recent administrations, the annual cost of ...

Waterhouse is due to take the helm of CSL on 1st February next year, around a year after Paul McKenzie abruptly departed the ...

Hibsago, has been approved in the US, its second major market after Japan, giving patients hope of a functional cure without ...

That one chance rests on a set of decisions about data and the systems that hold it. Those decisions are usually made quickly ...

While relatively uncommon, UC that starts in childhood tends to be more extensive and severe than when it emerges in ...

Novo continues to build the case for its new weight-loss candidate CagriSema, pointing to new data that show strong efficacy ...

A compounded version of Eli Lilly's injectable weight-loss and diabetes therapy tirzepatide, produced and sold by Apothecary ...

A year after signing a first deal with Hansoh worth up to $1.45 billion, Roche has returned for another that could be more ...

Merck KGaA has reached a deal to acquire UK-based Silence Therapeutics in ​an all-cash, $1.3 billion deal that will boost its ...

GSK's PD-1 inhibitor Jemperli has been cleared by the FDA as a pre-operative treatment for rectal cancer that can eliminate ...

Shah Capital has ended its attempts to exert influence over vaccine developer Novavax, bringing more than years of activism ...

Swiss biotech Nouscom has closed a €120 million ($135 million) fourth-round financing for a vaccine to protect people with a ...